SAB Biotherapeutics (SABS) Other Non Operating Income (2021 - 2026)

SAB Biotherapeutics has reported Other Non Operating Income for 6 years, with the latest figure at $626873.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 14.68% year-over-year to $626873.0; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 27.33% YoY), and the FY2025 full-year result was $3.1 million, up 27.77% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $626873.0, down from $1.5 million in the prior quarter.
• The five-year high for Other Non Operating Income was $7.8 million in Q1 2022, with the low at $1527.0 in Q3 2022.
• Historically, Other Non Operating Income has averaged $1.1 million across 5 years, with a median of $546627.0 in 2025.
• Annual changes were most pronounced in 2022 — Other Non Operating Income slumped 61.37% — and 2023, when it jumped 6264.31%.
• SAB Biotherapeutics' Other Non Operating Income stood at $32227.0 in 2022, then jumped by 948.52% to $337906.0 in 2023, then soared by 153.03% to $854997.0 in 2024, then surged by 78.44% to $1.5 million in 2025, then sank by 58.91% to $626873.0 in 2026.
• The last three Other Non Operating Income figures came in at $626873.0 (Q1 2026), $1.5 million (Q4 2025), and $765881.0 (Q3 2025), per Business Quant data.